Conexeu Sciences reports widened net loss and cash shortfall

Conexeu Sciences said widening net losses and insufficient cash for 12 months without new financing reflect higher marketing, staffing and regulatory costs, while it launches a prepaid IR campaign and targets filing an FDA 510(k) in Q1 2027.